Apr 08, 2020
Roche Tops the Pharmaceutical Innovation Index for the First Time; AstraZeneca Ranks 1st for Its Pipeline
Oct 11, 2019
Shionogi enters into a new license agreement and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
Jun 24, 2019
Shionogi Concludes Licensing Agreements with Eddingpharm for Lusutrombopag, a Thrombopoietin Receptor Agonist
Dec 05, 2018
Vast Therapeutics Announces Series A Funding
Jun 06, 2018
Shionogi enters into a license and research collaboration for the treatment of mycobacterial diseases with Hsiri Therapeutics, Inc.
Feb 06, 2018
Global Swine and Avian Influenza Drug Development Pipeline Review 2017 Featuring Gemmus Pharma, Aphios, Fides Pharma, Inovio, Microbiotix, NanoViricides, Shionogi and Tria Bioscience
Jan 23, 2018
Superbugs: First Independent Comparison of Pharma Companies' Efforts to Address Drug-resistant Infections
Jan 05, 2018
PharmaIN and Shionogi Announce Collaboration and $17M Securities Purchase Agreements
Oct 20, 2017
Confirmatory Results of the Second Phase 3 Lusutrombopag (S-888711) Study (L-PLUS 2) Presented at the 2017 Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD)
Sep 28, 2017
Shionogi To Highlight Research On Cefiderocol (S-649266), A Siderophore Cephalosporin, And S-033188, A Cap-Dependent Endonuclease Inhibitor For Treatment Of Influenza, At IDWeek 2017
Sep 25, 2017
Shionogi Announces Results for Lusutrombopag (S-888711) Phase 3 Study (L-PLUS2) for the Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing Elective Invasive Procedures
Sep 13, 2017
S-033188 Phase 3 CAPSTONE-1 Study Results for Treatment of Influenza Presented at the European Scientific Working Group on Influenza Conference
Aug 03, 2017
Shionogi Inc. President and CEO John Keller to Receive Innovation Award from NY American Chemical Society CME Group
Jul 24, 2017
Shionogi Announces Positive Top-Line Results for S-033188 Phase 3 Study (CAPSTONE-1) in Otherwise Healthy Influenza Patients
Jun 01, 2017
Further Evidence Supports Cefiderocol Activity Against MDR Gram-Negative Pathogens: Data Presented at the American Society for Microbiology Microbe (ASM) Meeting